Area of research
Molecular Biology · Oncology
Research interest
Research interests include PARP inhibition in cancer therapy, DNA Repair Mechanisms, CRISPR and Genetic Engineering, and Cancer Genomics and Diagnostics.
Data from Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
Data from Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance
Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance
Abstract 932: Reversing PARP inhibitor resistance by targeting the replication stress response
Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer
Abstract LB-176: The human androgen receptor regulates DNA damage response (DDR) in prostate cancer
Small-molecule–induced DNA damage identifies alternative DNA structures in human genes